Amid the topmost stocks in today’s market is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Regeneron Pharmaceuticals, Inc. had a market cap of 57050.13, indicating that it has a good hold on the market value of the shares outstanding. The current market cap of Regeneron Pharmaceuticals, Inc. exhibits the basic determinant of asset allocation and risk-return parameters for its stocks.
The P/E of Regeneron Pharmaceuticals, Inc. is currently valued at 106.86 allowing its investors to analyze the company’s stock valuation and its shares relative to the income of the company that it makes. With the constructive P/E value of Regeneron Pharmaceuticals, Inc., the investors are able to forecast the positive earnings growth of the company.
The forward P/E of Regeneron Pharmaceuticals, Inc. is at 36.63 signifying the uses of estimated net earnings over the next 12 months. Investors will be getting a good grip in comparing the current earnings of the company to estimated future earnings.
With its low price-to-sales ratio of 14.98, the company is evidently a better investment since the investors are paying a lower amount for each unit of sales. However, the company sales do not necessarily expose the entire picture, as it might be unprofitable with a low P/S ratio.
The price-to-book ratio of 17.18 for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) implies that investors are highly hopeful for the organization to create more value from the given set of assets. The market value of the firm’s assets are considerably higher in contrast to their accounting value. The current P/B amount of Regeneron Pharmaceuticals, Inc. best indicates the value approach in differentiating good from the bad. The ratio also provides a clue to how much investors are paying for what would be left if the company went bankrupt immediately.
The target payout ratio for Regeneron Pharmaceuticals, Inc. is currently measuring at 0.00%, outlining what size the company’s dividends should be. It also demonstrates a stable dividend policy for Regeneron Pharmaceuticals, Inc. connected to the long-run, with viable earnings.
The EPS for Regeneron Pharmaceuticals, Inc. is valued at 5.13 with an EPS growth this year at -19.40%. The company’s EPS growth for the following year is valued at 18.47%, indicating an EPS value of 41.20% for the past 5 years, and an EPS value of 21.53% for the coming five years.
Regeneron Pharmaceuticals, Inc.’s sales for the past 5 years rolls at 49.40%, exhibiting an EPS growth from quarter-to-quarter at 154.90%. The sales growth of the company is 56.70% at the moment, indicating the average sales volume of the company’s products and services that have typically improved year-to-year.
Company’s existing stock price is at 546 with a change in price of -0.40%. As of now, the target price for the company is measuring at 625. Regeneron Pharmaceuticals, Inc.’s ROA is rolling at 13.30%, following the ROI of 12.50%. Quick and current ratio is valued at 3.4 and 3.6 respectively.